
Difficulty Playing Music Follows Treatment for BC
Over a quarter of musicians experienced difficulty with musical endeavors during or after the breast cancer treatment with 57% reporting unresolved issues at survey time. Chemotherapy emerged as the most impactful treatment with 71% of recipients citing it as most detrimental to musical ability.
METHODOLOGY:
Playing instruments and singing require high levels of fine sensorimotor control, making musicians potentially vulnerable to unique manifestations of breast cancer treatment toxicities. These include chemotherapy-induced peripheral neuropathy, upper-extremity dysfunction after surgery and radiation, and joint pain associated with aromatase inhibitors.
A nine-item Musical Toxicity Questionnaire was distributed to 4075 participants in the Mayo Clinic Breast Cancer Registry, achieving a 46% response rate with 1871 respondents.
Researchers identified musicians by asking if participants played an instrument or sang in the last 10 years with 535 qualifying respondents reporting 802 unique musical endeavors.
Analysis included assessment of acute musical toxicity during or after the treatment with participants detailing specific symptoms, affected musical attributes, and timeline of resolution.
Multivariable logistic regression and classification tree analyses were conducted to evaluate relationships between acute musical toxicity and treatment characteristics.
TAKEAWAY:
Among 535 self-identified musicians, 27% (144/535) reported acute musical toxicity with decreased endurance being the most common difficulty (64%, 92/144) followed by 'decreased accuracy' (44%, 64/144).
Younger patients reported significantly more acute musical toxicity (P =.005), with 34% (14/41) of those younger than 40 years and 36% (42/117) of those aged 40-49 years affected.
Multivariable analysis revealed that the receipt of chemotherapy (P <.001) and comprehensive regional nodal irradiation vs no radiation (P =.023) were significantly associated with acute musical toxicity.
Patient-Reported Outcomes Measurement Information System scores at 1 year post-diagnosis showed that each additional point in mental and physical health scores decreased acute musical toxicity odds by 8.6% and 14%, respectively.
IN PRACTICE:
'These results will help oncology care teams counsel musicians, answer questions about impacts on musicality, and provide a timeline for resolution of musical symptoms,' the authors of the study wrote.
SOURCE:
This study was led by Jessica F. Burlile, MD, Mayo Clinic in Rochester, New York. It was published online in JCO Oncology Practice.
LIMITATIONS:
According to the authors, this study faced several limitations including recall bias with a median time of 5.3 years from diagnosis to survey completion. The researchers noted that musical abilities may have declined due to lack of practice, injuries, or natural aging during this period, which was not accounted for. Additionally, the survey did not include items specific to neurocognitive function, though multiple respondents noted difficulty with processing music or sight reading in free response areas.
DISCLOSURES:
This study received support from Department of Radiation Oncology Innovation Funds, Mayo Clinic, and a grant from the Mayo Fellows Association. Additional disclosures are noted in the original article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound
By Maggie Fick and Bhanvi Satija SEATTLE (Reuters) -U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with their weight-loss injections, analysts and investors say, in a departure from the usual practice of charging more for new medicines despite pressure to cut prices. Neither drugmaker has disclosed pricing plans for their new daily oral medications. With regulatory approvals and launches still months away, pricing plans could change. Denmark-based Novo expects approval later this year and to launch soon after, while Indianapolis-based Lilly expects to launch by August 2026. Novo's Wegovy and Lilly's Zepbound, administered as weekly injections, are the only highly effective weight-loss drugs targeting the GLP-1 hormone, and the United States is their biggest market. U.S. list prices are about $1,000 per month or more, with both companies offering a monthly supply for $499 to customers paying cash rather than using health insurance. Both companies have said they developed oral weight-loss drugs to meet patient needs and widen access to the market, mindful that some people are averse to injections. The pills, however, are not more effective than the injections. Lilly said this month its pill orforglipron cut weight by 12.4% after 72 weeks in a trial. That compares with weight loss of 15% for Novo's daily oral semaglutide. Both trail Lilly's injection at up to 21%. UBS analyst Trung Huynh said that will cap Lilly's pricing. The price is "probably going to come on par with the current drugs today or slightly lower," Huynh said. TD Cowen analyst Michael Nedelcovych said he expects Novo's pill to debut near Wegovy's price, citing the precedent of its diabetes pill Rybelsus being priced at parity with injection Ozempic, the diabetes-treatment version of Wegovy. Novo executives told analysts this month they were not in a hurry for discount pricing for the new pill. Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will account for a percentage share of the global obesity drug market in the mid-teens by 2030, which could reach $150 billion by then. GROWING CASH PAY U.S. doctors, patients and insurers are pressing for lower prices to make the weight-loss drugs more affordable for the 40% of Americans who are obese. Typically, drugmakers launch new drugs at higher prices, citing scientific advances. President Donald Trump and lawmakers from both parties have urged the companies to reduce U.S. prices. Novo declined to comment on pricing, pointing to August 6 comments by David Moore, its U.S. operations head, saying that the company may tap customers paying cash directly via its new NovoCare pharmacy, which was launched this year to sell Wegovy outside of insurance. A Lilly spokesperson called it premature to comment on pricing and launch plans for its pill because the company has not yet submitted data for regulatory approval. Peak annual sales forecasts for Lilly's orforglipron fell to as low as $10 billion after its trial data from earlier estimates of up to $30 billion, according to a Reuters review of analyst estimates. HSBC forecasts $15 billion in peak annual sales for Novo's pill, while Barclays expects only $1 billion. MANUFACTURING VOLUME A key question is how much supply will be available at the time of launch. Shortages of injectable GLP-1s in 2023 and 2024 opened the U.S. market to cheaper compounded versions as the manufacturers failed to anticipate the huge demand. "It's all about scale and pricing," said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares. Gade pointed to Novo's manufacturing challenge. The pill form requires about 75 times more active ingredient than the highest-dose Wegovy injection, two analysts told Reuters. Lilly has said it already has $808.5 million in orforglipron inventory for next year's expected launch. Novo has said it will launch its pill without supply constraints after billions of dollars in investment to expand semaglutide production. Despite the high production needs, Novo is unlikely to debut its pill at a higher price than Wegovy, said Karen Andersen, healthcare strategist at Morningstar. "Particularly in the growing cash-pay market, I doubt it can risk a launch at a premium to Wegovy," Andersen added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Forest Lake Endodontics Welcomes Endodontist Dr. Linda Liu to the Practice
FOREST LAKE, Minn., Aug. 18, 2025 /PRNewswire/ -- Forest Lake Endodontics in Forest Lake, Minnesota, announced today that endodontist Dr. Linda Liu has joined its team, bringing advanced training in root canal treatment and a strong commitment to patient-centered care. Dr. Liu earned her Bachelor of Science in Microbiology with a minor in Mathematics from the University of Michigan in Ann Arbor. She went on to obtain her Doctor of Dental Surgery degree and complete a General Practice Residency at the University of Toledo. Dr. Liu then specialized in Endodontics at the University of Minnesota, where she also earned her Master's degree. Residing in Blaine with her husband, Philip, an anesthesiology resident at the University of Minnesota, and their goldendoodle, Dr. Liu looks forward to serving patients in the greater Forest Lake community. Outside of her professional life, she enjoys playing the piano, pickleball, traveling to new destinations, and exploring local restaurants. Forest Lake Endodontics has served the Twin Cities metro area for 6 years, specializing in root canal therapy and other advanced endodontic treatments in a welcoming environment. The practice partners closely with referring dentists to provide patients with seamless, high-quality care. "I am honored to join the talented team at Forest Lake Endodontics," said Dr. Liu. "It is incredibly rewarding to relieve patients' discomfort and preserve their natural teeth. I look forward to contributing my skills and working alongside my colleagues to deliver the highest level of care." Forest Lake Endodontics provides the following services: Root canal treatment. Root canal retreatment. Endodontic surgery (apicoectomy). Emergency dental care for traumatic injuries. Advanced diagnostics for tooth pain. External root resorption repairs. About Forest Lake Endodontics Forest Lake Endodontics specializes in advanced endodontic treatments designed to save natural teeth and restore oral health. The practice combines cutting-edge technology with a patient-first philosophy to deliver exceptional results. For more information, visit or contact Forest Lake Endodontics, 1420 Lake Street S., Suite 200a, Forest Lake, MN 55025, 651-464-9888. View original content to download multimedia: SOURCE Forest Lake Endodontics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

E&E News
10 minutes ago
- E&E News
Breaking down summer's mosquito-borne diseases
West Nile virus in Italy, chikungunya in China, dengue in France. With summer in full bloom, mosquitoes are doing what mosquitoes do: keeping you up at night and spreading vector-borne viruses. European countries, particularly in the south, have already reported their share of outbreaks this summer, while China is seeing an alarming spike in chikungunya cases. Although these diseases are not new, their presence in Europe is shifting as climate change makes environmental conditions more habitable for certain types of mosquito. Here's what you need to know. Advertisement The West Nile virus is endemic to Europe — meaning it is found across the continent all year round. The virus is spread by Culex pipiens, or the northern house mosquito (native to Europe), which spreads it from infected birds to humans and some animals. It is asymptomatic in 80 percent of humans — but can lead to fever and, in severe cases, cause neurological diseases and become deadly.